ProCE Banner Activity

How We Select Treatment in R/R Myeloma: A Conversation With 3 Experts

Clinical Thought
With rapid advances and new drug approvals, it is increasingly challenging to select treatment for advanced myeloma. Read our conversation on current best practices.

Released: March 29, 2021

Expiration: March 28, 2022

Share

Faculty

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Suzanne Lentzsch

Suzanne Lentzsch, MD, PhD

Director, Multiple Myeloma and Amyloidosis Program
Associate Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Saad Z. Usmani

Saad Z. Usmani, MD, MBA, FACP

Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
Professor
Weill Cornell Medical College, Cornell University
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Bristol Myers Squibb

Janssen administered by Scientific Affairs

Oncopeptides

Program Director Disclosure

Program Director

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Shaji K. Kumar, MD, has disclosed that he has received funds for research support from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, MedImmune, Oncopeptides, Takeda, and TeneoBio and consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Oncopeptides, and Takeda.

Faculty Disclosure

Primary Author

Suzanne Lentzsch, MD, PhD

Director, Multiple Myeloma and Amyloidosis Program
Associate Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Suzanne Lentzsch, MD, PhD, has disclosed that she has received funds for research support from Karyopharm and Sanofi; has received consulting fees from AbbVie, Caelum, Celularity, GlaxoSmithKline, Janssen, Karyopharm, Sanofi, Sorrento, and Takeda; has received salary from Magenta; and has ownership interest in Caelum.

Saad Z. Usmani, MD, MBA, FACP

Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
Professor
Weill Cornell Medical College, Cornell University
New York, New York

Saad Z. Usmani, MD, MBA, FACP, has disclosed that he has received funds for research support and consulting fees from Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Sanofi, Seattle Genetics, SkylineDx, Takeda, and TeneoBio and fees for non-CME/CE services from Amgen, Bristol-Myers Squibb/Celgene, Janssen, Sanofi, and Takeda.